Synthetic approaches to 1,2,4-triazolo[5,1-<i>c</i>][1,2,4]triazin-7-ones as basic heterocyclic structures of the antiviral drug Riamilovir (“Triazavirin®”) active against SARS-CoV-2 (COVID-19)-Reference-Cited by-同舟云学术

Synthetic approaches to 1,2,4-triazolo[5,1-c][1,2,4]triazin-7-ones as basic heterocyclic structures of the antiviral drug Riamilovir (“Triazavirin®”) active against SARS-CoV-2 (COVID-19)

Published:2022 Issue:9 Volume:20 Page:1828-1837
ISSN:1477-0520
Container-title:Organic & Biomolecular Chemistry
language:en
Short-container-title:Org. Biomol. Chem.

Author:

Artem'ev Grigory A.¹²,Rusinov Vladimir L.¹²,Kopchuk Dmitry S.¹²,Savchuk Maria I.¹²,Santra Sougata²^ORCID,Ulomsky Eugeny N.¹²,Zyryanov Grigory V.¹²,Majee Adinath³^ORCID,Du Weijie⁴,Charushin Valery N.¹²,Chupakhin Оleg N.¹²^ORCID

Affiliation:

1. I. Ya. Postovskiy Institute of Organic Synthesis, UB of the RAS, 22 S. Kovalevskoy Str., Yekaterinburg, 620219, Russian Federation

2. Ural Federal University, 19 Mira str., Yekaterinburg, 620002, Russian Federation

3. Department of Chemistry; Visva-Bharati (A Central University), Santiniketan 731235, India

4. Department of Pharmacology (State-Province Key Laboratories of Biomedicine Pharmaceutics of China, Key Laboratory of Cardiovascular research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, 150081, China

Abstract

In this review article, the currently available synthetic approaches to 1,2,4-triazolo[5,1-c][1,2,4]triazin-7-ones have been discussed. This moiety is considered as a basic heterocyclic structure of the antiviral drug Riamilovir (“Triazavirin®”).

Funder

Russian Foundation for Basic Research

Ministry of Science and Higher Education of the Russian Federation

National Natural Science Foundation of China

Publisher

Royal Society of Chemistry (RSC)

Subject

Organic Chemistry,Physical and Theoretical Chemistry,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2022/OB/D1OB02125G

Reference72 articles.

1. Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy